<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01594476</url>
  </required_header>
  <id_info>
    <org_study_id>8120</org_study_id>
    <nct_id>NCT01594476</nct_id>
  </id_info>
  <brief_title>Early Postpartum Intrauterine Device (IUD) Placement</brief_title>
  <official_title>Early Versus Standard Interval Postpartum Intrauterine Device (IUD) Placement at 3 Weeks or 6 Weeks Following Delivery: A Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women who have just given birth are at high risk for rapid repeat pregnancy, which can lead
      to negative consequences during the subsequent pregnancy. Providers have traditionally
      delayed starting birth control, especially placement of intrauterine devices (IUDs),
      post-delivery for a number of reasons. The first postpartum visit after a woman has given
      birth is typically scheduled for 6 weeks after her delivery, during which she is typically
      provided with her chosen method of birth control. This study will evaluate two different IUD
      placement times: 3 weeks and 6 weeks after delivery. This will allow the researchers to
      determine if placement time affects a woman's follow-through obtaining the IUD and keeping it
      inserted in place. The researchers will also look at bleeding patterns and patient/provider
      satisfaction with the IUD placement
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to investigate whether early interval placement of a postpartum IUD
      at 3 weeks postpartum, compared to the usual 6 weeks postpartum, is associated with greater
      uptake of the IUD by 3 months after delivery. Many women do not return for a follow up visit.
      We will investigate whether they are more likely to return and to receive an IUD if the
      follow up visit is earlier. Measures of 6 month IUD continuation, subject acceptability,
      safety and efficacy will also be examined. This prospective, randomized, controlled trial
      will enroll approximately 240 women at our academic tertiary care hospital in the United
      States. Participants will be recruited from women who deliver a live-born singleton infant at
      greater than 32 weeks gestation and who have indicated interest in obtaining intrauterine
      contraception. Subjects will choose to receive either a levonorgestrel-containing IUS
      (Mirena) or copper T380A IUD (ParaGard). Enrolled subjects will be randomized to IUD
      placement at either 3 weeks (+/- 3 days) or 6 weeks (+/- 3 days) after their delivery date.
      Women will be followed by phone contacts at 3 months and 4 months and will have a clinic
      visit with an ultrasound at 6 months after delivery. The IUD position in the uterus and the
      uterine size will be assessed at 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Incomplete study enrollment prior to depletion of funding
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects With an IUD at 3 Months Postpartum</measure>
    <time_frame>Three months after delivery</time_frame>
    <description>Subjects will be contacted by phone or email at 3 months after delivery. We will compare the proportion of subjects who report having an IUD in place at 3 months after delivery of those who are randomized to each group (placement at either 3 weeks or 6 weeks) .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction With the Timing of IUD Placement.</measure>
    <time_frame>Immediately following IUD placement.</time_frame>
    <description>Subjects were asked to record their overall satisfaction with the timing of the IUD placement on a 100 millimeter (mm) visual analog scale (VAS). A VAS is a 100 mm horizontal line with anchors stating &quot;very dissatisfied&quot; and &quot;very satisfied.&quot; The VAS score is calculated by measuring the distance in millimeters between the left end of the scale and the intersection of a vertical mark placed by the subject. Maximum score is 100 (range 0-100). Higher scores indicate higher satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine Thickness at the Fundus</measure>
    <time_frame>At IUD placement</time_frame>
    <description>Transvaginal ultrasound will be performed immediately following IUD placement. The thickness of the uterine myometrium at the fundus from the endometrium to the outer edge of the serosa will be measured in centimeters using an ultrasound caliper in the sagittal view.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With an IUD at 6 Months Postpartum</measure>
    <time_frame>Six months after delivery</time_frame>
    <description>Subjects will return to clinic for an ultrasound and exam at six months after delivery. We will compare the proportion of subjects with an IUD at this time of those randomized to each placement timing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Adverse Events</measure>
    <time_frame>Six months after delivery</time_frame>
    <description>Subjects will be followed for 6 months each. Over the 6 month study period, the number and proportion of subjects who experience adverse events including treatment for infection, IUD expulsion or IUD perforation will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain With IUD Placement</measure>
    <time_frame>At the time of IUD placement.</time_frame>
    <description>Subjects were asked to record their current pain immediate at the time of the IUD placement on a 100 millimeter (mm) visual analog scale (VAS). A VAS is a 100 mm horizontal line with anchors stating &quot;no pain&quot; and &quot;worst pain in my life.&quot; The VAS score is calculated by measuring the distance in millimeters between the left end of the scale and the intersection of a vertical mark placed by the subject. Maximum score is 100 (range 0-100). Higher scores indicate higher pain. The distance from the left side of the 10 cm line to the mark will be measured in millimeters and compared between randomization groups if they received an IUD at the allocated timing of 18-24 or 39-45 days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Levonorgestrel IUS insertion at 3 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IUD placement at 3 weeks after delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levonorgestrel IUS insertion at 6 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IUD placement at 6 weeks after delivery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel IUS</intervention_name>
    <description>20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device</description>
    <arm_group_label>Levonorgestrel IUS insertion at 3 weeks</arm_group_label>
    <arm_group_label>Levonorgestrel IUS insertion at 6 weeks</arm_group_label>
    <other_name>Mirena IUS</other_name>
    <other_name>Paragard IUD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  18 years or older

          -  Voluntarily requesting either copper T380A or levonorgestrel IUD placement for
             postpartum contraception

          -  Within 5 days of vaginal or cesarean delivery of live born infant â‰¥32 0/7 weeks at the
             time of enrollment

          -  English or Spanish speaking

          -  Able to give consent and agree to terms of the study

          -  No contraindications to use of either intrauterine device

        Exclusion Criteria:

          -  Preterm delivery prior to 32 weeks gestation

          -  Recent pregnancy with multiple gestation

          -  Current incarceration

          -  Known congenital or acquired uterine anomaly, including fibroids that distort the
             uterine cavity

          -  Current or recent pelvic infection (chorioamnionitis treated for fever in labor only
             is not an exclusion)

          -  Suspected hypersensitivity or contraindication to the chosen IUD

          -  No insurance coverage for postpartum care, including Citizen Alien Waived Emergent
             Medical (CAWEM)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maureen Baldwin, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 9, 2012</study_first_submitted>
  <study_first_submitted_qc>May 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2012</study_first_posted>
  <results_first_submitted>December 20, 2017</results_first_submitted>
  <results_first_submitted_qc>January 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 11, 2019</results_first_posted>
  <last_update_submitted>January 9, 2019</last_update_submitted>
  <last_update_submitted_qc>January 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Maureen Baldwin</investigator_full_name>
    <investigator_title>Instructor, Ob/Gyn, Fellow in Family Planning</investigator_title>
  </responsible_party>
  <keyword>Postpartum</keyword>
  <keyword>Contraception</keyword>
  <keyword>Intrauterine device</keyword>
  <keyword>Intrauterine system</keyword>
  <keyword>Mirena</keyword>
  <keyword>Paragard</keyword>
  <keyword>Uterine involution</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IUD Insertion at 3 Weeks</title>
          <description>IUD placement at 3 weeks after delivery.
Levonorgestrel IUS: 20 mcg levonorgestrel per day in intrauterine system for Mirena IUS or Copper T intrauterine device</description>
        </group>
        <group group_id="P2">
          <title>IUD Insertion at 6 Weeks</title>
          <description>IUD placement at 6 weeks after delivery.
Levonorgestrel IUS: 20 mcg levonorgestrel per day in intrauterine system for Mirena IUS or Copper T intrauterine device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Intervention</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Excluded After Allocation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>IUD Removal</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>IUD Expulsion</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Pregnant</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Levonorgestrel IUS Insertion at 3 Weeks</title>
          <description>IUD placement at 3 weeks after delivery.
Levonorgestrel IUS: 20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device</description>
        </group>
        <group group_id="B2">
          <title>Levonorgestrel IUS Insertion at 6 Weeks</title>
          <description>IUD placement at 6 weeks after delivery.
Levonorgestrel IUS: 20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="97"/>
            <count group_id="B3" value="197"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.8" spread="5.7"/>
                    <measurement group_id="B2" value="29.0" spread="5.8"/>
                    <measurement group_id="B3" value="28.6" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="197"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insurance type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Public insurance</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Private insurance</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Planned pregnancy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Unplanned</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Planned</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Delivery type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Vaginal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Cesarean</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>High school/GED or less</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than high school</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Snyder Hope Scale</title>
          <description>The Snyder Hope Scale (Future Scale) is a 12-question validated survey that includes four questions that reflect agency, four that reflect pathways, and four that are distracters. Responses to this scale correlate well with other psychological tests designed to assess optimism, expectancy for attaining goals, and self-esteem. The distracter questions are not scored. The maximum total score is 64 (range 0-64; max 8 points per 8 questions scored and added). Each subscale has a maximum total score of 32 (range 0-32). Higher total score and subscale scores indicate better agency and pathways.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Future Scale total score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.2" spread="5.4"/>
                    <measurement group_id="B2" value="45.9" spread="6.7"/>
                    <measurement group_id="B3" value="46.5" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agency subscale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.8" spread="3.0"/>
                    <measurement group_id="B2" value="22.9" spread="4.1"/>
                    <measurement group_id="B3" value="23.4" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pathway subscale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.4" spread="3.2"/>
                    <measurement group_id="B2" value="22.8" spread="3.8"/>
                    <measurement group_id="B3" value="23.1" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Social-Support Scale</title>
          <description>The Multidimensional Scale of Perceived Social Support (MDSS) is a 12-question validated survey to assess perceived social support, another possible indicator for the ability to carry out a plan. The scores can be separated into 3 subscale domains for perceived support from family, friends, and significant other. Maximum total score is 84 (range 0-84), which included added subscale scores of maximum 28 (0-28) for 4 questions each. Higher scores indicate more perceived social support.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>MDSS total score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.8" spread="9.0"/>
                    <measurement group_id="B2" value="63.5" spread="10.7"/>
                    <measurement group_id="B3" value="64.7" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family subscale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.0" spread="3.6"/>
                    <measurement group_id="B2" value="20.4" spread="5.6"/>
                    <measurement group_id="B3" value="21.2" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Friends subscale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.3" spread="4.2"/>
                    <measurement group_id="B2" value="20.5" spread="5.2"/>
                    <measurement group_id="B3" value="20.9" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Significant other subscale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.0" spread="2.0"/>
                    <measurement group_id="B2" value="22.4" spread="3.2"/>
                    <measurement group_id="B3" value="22.7" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjects With an IUD at 3 Months Postpartum</title>
        <description>Subjects will be contacted by phone or email at 3 months after delivery. We will compare the proportion of subjects who report having an IUD in place at 3 months after delivery of those who are randomized to each group (placement at either 3 weeks or 6 weeks) .</description>
        <time_frame>Three months after delivery</time_frame>
        <population>Data analyzed as intent to treat regardless of when they had their IUD placed. This is IUD placed by 3 months in each group.</population>
        <group_list>
          <group group_id="O1">
            <title>IUD Insertion at 3 Weeks</title>
            <description>IUD placement at 3 weeks after delivery.
Levonorgestrel IUS: 20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device</description>
          </group>
          <group group_id="O2">
            <title>IUD Insertion at 6 Weeks</title>
            <description>IUD placement at 6 weeks after delivery.
Levonorgestrel IUS: 20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With an IUD at 3 Months Postpartum</title>
          <description>Subjects will be contacted by phone or email at 3 months after delivery. We will compare the proportion of subjects who report having an IUD in place at 3 months after delivery of those who are randomized to each group (placement at either 3 weeks or 6 weeks) .</description>
          <population>Data analyzed as intent to treat regardless of when they had their IUD placed. This is IUD placed by 3 months in each group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction With the Timing of IUD Placement.</title>
        <description>Subjects were asked to record their overall satisfaction with the timing of the IUD placement on a 100 millimeter (mm) visual analog scale (VAS). A VAS is a 100 mm horizontal line with anchors stating &quot;very dissatisfied&quot; and &quot;very satisfied.&quot; The VAS score is calculated by measuring the distance in millimeters between the left end of the scale and the intersection of a vertical mark placed by the subject. Maximum score is 100 (range 0-100). Higher scores indicate higher satisfaction.</description>
        <time_frame>Immediately following IUD placement.</time_frame>
        <population>Includes all subjects enrolled on protocol who underwent IUD placement at a study visit at any timing prior to 3 months postpartum. Comparison is based on randomization timing but actual timing of placement may have differed. Numbers differ from primary outcome due to removals and expulsion prior to 3 months, and placement outside study visits.</population>
        <group_list>
          <group group_id="O1">
            <title>IUD Insertion at 3 Weeks</title>
            <description>IUD placement at 3 weeks after delivery.
Levonorgestrel IUS: 20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device</description>
          </group>
          <group group_id="O2">
            <title>IUD Insertion at 6 Weeks</title>
            <description>IUD placement at 6 weeks after delivery.
Levonorgestrel IUS: 20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction With the Timing of IUD Placement.</title>
          <description>Subjects were asked to record their overall satisfaction with the timing of the IUD placement on a 100 millimeter (mm) visual analog scale (VAS). A VAS is a 100 mm horizontal line with anchors stating &quot;very dissatisfied&quot; and &quot;very satisfied.&quot; The VAS score is calculated by measuring the distance in millimeters between the left end of the scale and the intersection of a vertical mark placed by the subject. Maximum score is 100 (range 0-100). Higher scores indicate higher satisfaction.</description>
          <population>Includes all subjects enrolled on protocol who underwent IUD placement at a study visit at any timing prior to 3 months postpartum. Comparison is based on randomization timing but actual timing of placement may have differed. Numbers differ from primary outcome due to removals and expulsion prior to 3 months, and placement outside study visits.</population>
          <units>mm on VAS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.6" spread="17.2"/>
                    <measurement group_id="O2" value="93.5" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Uterine Thickness at the Fundus</title>
        <description>Transvaginal ultrasound will be performed immediately following IUD placement. The thickness of the uterine myometrium at the fundus from the endometrium to the outer edge of the serosa will be measured in centimeters using an ultrasound caliper in the sagittal view.</description>
        <time_frame>At IUD placement</time_frame>
        <population>Subjects who had their IUD placed at the allocated timing of 18-24 days versus 39-45 days</population>
        <group_list>
          <group group_id="O1">
            <title>IUD Insertion at 3 Weeks</title>
            <description>IUD placement at 3 weeks after delivery.
Levonorgestrel IUS: 20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device</description>
          </group>
          <group group_id="O2">
            <title>IUD Insertion at 6 Weeks</title>
            <description>IUD placement at 6 weeks after delivery.
Levonorgestrel IUS: 20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device</description>
          </group>
        </group_list>
        <measure>
          <title>Uterine Thickness at the Fundus</title>
          <description>Transvaginal ultrasound will be performed immediately following IUD placement. The thickness of the uterine myometrium at the fundus from the endometrium to the outer edge of the serosa will be measured in centimeters using an ultrasound caliper in the sagittal view.</description>
          <population>Subjects who had their IUD placed at the allocated timing of 18-24 days versus 39-45 days</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.8"/>
                    <measurement group_id="O2" value="1.7" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With an IUD at 6 Months Postpartum</title>
        <description>Subjects will return to clinic for an ultrasound and exam at six months after delivery. We will compare the proportion of subjects with an IUD at this time of those randomized to each placement timing.</description>
        <time_frame>Six months after delivery</time_frame>
        <population>Population is subject randomization groups.</population>
        <group_list>
          <group group_id="O1">
            <title>IUD Insertion at 3 Weeks</title>
            <description>IUD placement at 3 weeks after delivery.
Levonorgestrel IUS: 20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device</description>
          </group>
          <group group_id="O2">
            <title>IUD Insertion at 6 Weeks</title>
            <description>IUD placement at 6 weeks after delivery.
Levonorgestrel IUS: 20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With an IUD at 6 Months Postpartum</title>
          <description>Subjects will return to clinic for an ultrasound and exam at six months after delivery. We will compare the proportion of subjects with an IUD at this time of those randomized to each placement timing.</description>
          <population>Population is subject randomization groups.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Adverse Events</title>
        <description>Subjects will be followed for 6 months each. Over the 6 month study period, the number and proportion of subjects who experience adverse events including treatment for infection, IUD expulsion or IUD perforation will be assessed.</description>
        <time_frame>Six months after delivery</time_frame>
        <population>All subjects analyzed. This includes all subjects enrolled on protocol and allocated. There were no adverse events in the subjects excluded after allocation.</population>
        <group_list>
          <group group_id="O1">
            <title>IUD Insertion at 3 Weeks</title>
            <description>IUD placement at 3 weeks after delivery.
Levonorgestrel IUS: 20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device</description>
          </group>
          <group group_id="O2">
            <title>IUD Insertion at 6 Weeks</title>
            <description>IUD placement at 6 weeks after delivery.
Levonorgestrel IUS: 20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events</title>
          <description>Subjects will be followed for 6 months each. Over the 6 month study period, the number and proportion of subjects who experience adverse events including treatment for infection, IUD expulsion or IUD perforation will be assessed.</description>
          <population>All subjects analyzed. This includes all subjects enrolled on protocol and allocated. There were no adverse events in the subjects excluded after allocation.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>IUD expulsion</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>IUD perforation</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pregnancy with IUD in place</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Infection with IUD in place</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No known adverse events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain With IUD Placement</title>
        <description>Subjects were asked to record their current pain immediate at the time of the IUD placement on a 100 millimeter (mm) visual analog scale (VAS). A VAS is a 100 mm horizontal line with anchors stating &quot;no pain&quot; and &quot;worst pain in my life.&quot; The VAS score is calculated by measuring the distance in millimeters between the left end of the scale and the intersection of a vertical mark placed by the subject. Maximum score is 100 (range 0-100). Higher scores indicate higher pain. The distance from the left side of the 10 cm line to the mark will be measured in millimeters and compared between randomization groups if they received an IUD at the allocated timing of 18-24 or 39-45 days.</description>
        <time_frame>At the time of IUD placement.</time_frame>
        <population>Subjects analyzed by actual timing of IUD insertion</population>
        <group_list>
          <group group_id="O1">
            <title>18-24 Days After Vaginal Delivery</title>
            <description>IUD placement at 18-24 days after vaginal delivery.
Levonorgestrel IUS: 20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device</description>
          </group>
          <group group_id="O2">
            <title>39-45 Days After Vaginal Delivery</title>
            <description>IUD placement at 39-45 days after vaginal delivery.
Levonorgestrel IUS: 20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device</description>
          </group>
          <group group_id="O3">
            <title>18-24 Days After Cesarean Delivery</title>
            <description>IUD placement at 18-24 days after cesarean delivery.
Levonorgestrel IUS: 20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device</description>
          </group>
          <group group_id="O4">
            <title>39-45 Days After Cesarean Delivery</title>
            <description>IUD placement at 39-45 days after cesarean delivery.
Levonorgestrel IUS: 20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device</description>
          </group>
        </group_list>
        <measure>
          <title>Pain With IUD Placement</title>
          <description>Subjects were asked to record their current pain immediate at the time of the IUD placement on a 100 millimeter (mm) visual analog scale (VAS). A VAS is a 100 mm horizontal line with anchors stating &quot;no pain&quot; and &quot;worst pain in my life.&quot; The VAS score is calculated by measuring the distance in millimeters between the left end of the scale and the intersection of a vertical mark placed by the subject. Maximum score is 100 (range 0-100). Higher scores indicate higher pain. The distance from the left side of the 10 cm line to the mark will be measured in millimeters and compared between randomization groups if they received an IUD at the allocated timing of 18-24 or 39-45 days.</description>
          <population>Subjects analyzed by actual timing of IUD insertion</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" spread="16.4"/>
                    <measurement group_id="O2" value="23.0" spread="21.0"/>
                    <measurement group_id="O3" value="30.9" spread="27.3"/>
                    <measurement group_id="O4" value="32.1" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>IUD Insertion at 3 Weeks</title>
          <description>IUD placement at 3 weeks after delivery.
Levonorgestrel IUS: 20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device</description>
        </group>
        <group group_id="E2">
          <title>IUD Insertion at 6 Weeks</title>
          <description>IUD placement at 6 weeks after delivery.
Levonorgestrel IUS: 20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>IUD expulsion</sub_title>
                <description>Partial or complete expulsion</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Maureen Baldwin, MD MPH</name_or_title>
      <organization>Oregon Health &amp; Science University</organization>
      <phone>(503) 494-9762</phone>
      <email>schaum@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

